Leonetti Frida, Capoccia Danila, Coccia Federica, Casella Giovanni, Baglio Giovanni, Paradiso Francesca, Abbatini Francesca, Iossa Angelo, Soricelli Emanuele, Basso Nicola
Department of Clinical Sciences, Policlinico Umberto I, University of Rome Sapienza, Rome, Italy.
Arch Surg. 2012 Aug;147(8):694-700. doi: 10.1001/archsurg.2012.222.
To compare the effect of sleeve gastrectomy vs medical therapy on type 2 diabetes mellitus and other obesity-related comorbidities (obstructive sleep apnea syndrome, hypertension, and dyslipidemia) in prospectively enrolled and matched obese patients with type 2 diabetes.
A prospective cohort study. Morbidly obese patients with type 2 diabetes who either underwent sleeve gastrectomy or conventional therapy were followed up and assessed for their diabetic state and other comorbidities every 3 months for 18 months.
Centre for the Surgical-Medical Treatment of Morbid Obesity, Policlinico “Umberto I,” University of Rome “Sapienza,” Italy.
A total of 30 morbidly obese patients with type 2 diabetes who underwent sleeve gastrectomy (group A) and a total of 30 morbidly obese patients with type 2 diabetes who underwent conventional therapy (group B).
In group A, the preoperative mean (SD) body mass index, fasting plasma glucose level, and hemoglobin A1c level were 41.3 (6.0), 166.6 (68.1) mg/dL, and 7.9% (2.1%), respectively, and, at 18 months, these values were 28.3 (5.4), 96.2 (29.4) mg/dL, and 6.0% (1.5%), respectively. For 80% of patients, diabetes was resolved. With regard to other comorbidities, the prevalence of obstructive sleep apnea syndrome dropped from 50% to 10%, and patients reduced significantly their use of medication for hypertension and dyslipidemia. In group B, the preoperative mean (SD) body mass index, fasting plasma glucose level, and hemoglobin A1c level were 39.0 (5.5), 183.7 (63.5) mg/dL, and 8.1% (1.7%), respectively, and, at 18 months, these values were 39.8 (5.0), 150 (48) mg/dL, and 7.1% (1.3%), respectively. All patients remained diabetic and continued or increased their level of hypoglycemic therapy. With regard to other comorbidities, we observed an increase in the use of medication for hypertension and dyslipidemia, and the prevalence of obstructive sleep apnea syndrome did not change.
This study confirms the efficacy of sleeve gastrectomy in the treatment of morbidly obese type 2 diabetic patients when compared with conventional medical treatment.
比较袖状胃切除术与药物治疗对前瞻性纳入并匹配的肥胖2型糖尿病患者的2型糖尿病及其他肥胖相关合并症(阻塞性睡眠呼吸暂停综合征、高血压和血脂异常)的影响。
一项前瞻性队列研究。对接受袖状胃切除术或传统治疗的病态肥胖2型糖尿病患者进行随访,每3个月评估一次其糖尿病状态及其他合并症,为期18个月。
意大利罗马“萨皮恩扎”大学“翁贝托一世”综合医院病态肥胖外科-内科治疗中心。
共有30例接受袖状胃切除术的病态肥胖2型糖尿病患者(A组)和30例接受传统治疗的病态肥胖2型糖尿病患者(B组)。
A组术前平均(标准差)体重指数、空腹血糖水平和糖化血红蛋白水平分别为41.3(6.0)、166.6(68.1)mg/dL和7.9%(2.1%),18个月时,这些值分别为28.3(5.4)、96.2(29.4)mg/dL和6.0%(1.5%)。80%的患者糖尿病得到缓解。关于其他合并症,阻塞性睡眠呼吸暂停综合征的患病率从50%降至10%,患者显著减少了高血压和血脂异常药物的使用。B组术前平均(标准差)体重指数、空腹血糖水平和糖化血红蛋白水平分别为39.0(5.5)、183.7(63.5)mg/dL和8.1%(1.7%),18个月时,这些值分别为39.8(5.0)、150(48)mg/dL和7.1%(1.3%)。所有患者仍患有糖尿病,并继续或增加了降糖治疗水平。关于其他合并症,我们观察到高血压和血脂异常药物的使用增加,阻塞性睡眠呼吸暂停综合征的患病率没有变化。
本研究证实,与传统药物治疗相比,袖状胃切除术治疗病态肥胖2型糖尿病患者有效。